SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors

被引：3
|
作者：
Hu, Shanhu
Ke, Nan
Ren, Yixuan
Miljovska, Sofija
Rajagopal, Nisha
McKeown, Michael
Orlando, David
Sprott, Kevin
Choi, Yoon J.
Olson, Eric
Fritz, Christian C.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1151
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo
    Konstantinopoulos, Panagiotis A.
    Hodgson, Graeme
    Rajagopal, Nisha
    Johannessen, Liv
    Liu, Joyce F.
    Kirschmeier, Paul T.
    Zhou, Shan
    Cam Anh Tran
    Orlando, David
    Fritz, Christian
    di Tomaso, Emmanuelle
    Matulonis, Ursula A.
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7
    Hu, Shanhu
    Marineau, Jason J.
    Rajagopal, Nisha
    Hamman, Kristin B.
    Choi, Yoon Jong
    Schmidt, Darby R.
    Ke, Nan
    Johannessen, Liv
    Bradley, Michael J.
    Orlando, David A.
    Alnemy, Sydney R.
    Ren, Yixuan
    Ciblat, Stephane
    Winter, Dana K.
    Kabro, Anzhelika
    Sprott, Kevin T.
    Hodgson, J. Graeme
    Fritz, Christian C.
    Carulli, John P.
    di Tomaso, Emmanuelle
    Olson, Eric R.
    CANCER RESEARCH, 2019, 79 (13) : 3479 - 3491
  • [3] Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia
    Hodgson, Graeme
    Johannessen, Liv
    Rajagopal, Nisha
    Hu, Shanhu
    Orlando, David
    Eaton, Matthew
    McKeown, Michael
    Tyner, Jeffrey W.
    Kurtz, Stephen E.
    Sprott, Kevin
    Fritz, Christian
    Di Tomaso, Emmanuelle
    BLOOD, 2017, 130
  • [4] A phase 1 study of SY-1365, a selective CDK7 inhibitor, in adult patients with advanced solid tumors
    Tolcher, A.
    Do, K. T.
    di Tomaso, E.
    Waters, N.
    Stephens, K.
    Roth, D. A.
    Shapiro, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] PK/PD modeling of the first in-class, potent and selective covalent CDK7 inhibitor, SY-1365, provides mechanistic basis for intermittent dosing regimens in preclinical efficacy models of hematologic and solid tumors
    Waters, Nigel J.
    Hu, Shanhu
    Matzuka, Brett
    Hodgson, Graeme
    Ren, Yixuan
    Choi, Yoon
    Dykstra, Kevin
    Roberts, Christopher
    Sprott, Kevin
    di Tomaso, Emmanuelle
    Fritz, Christian
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [6] The development of a selective CDK7 inhibitor with anti-tumor activity
    Coombes, Raoul
    Cheiper
    Jogalekar, Ashutosh S.
    Brackow, Jan
    Ali, Simak
    Heathcote, Dean
    Kroll, Sebastian
    Bodo, S.
    Siwicka, Aleksandra
    Periyasamy, Manikandan
    Tolhurst, Robert
    Kanneganti, Seshu
    Snyder, James
    Liotta, Dennis
    Aboagye, Eric
    Barrett, Anthony
    CANCER RESEARCH, 2009, 69
  • [7] Potent anti-tumor activity of AUR102, a selective covalent inhibitor of CDK7
    Satyam, L. K.
    Poddutoori, R.
    Thiyagarajan, S.
    Mukherjee, S.
    Kaza, L. N.
    Charamanna, K.
    Marappan, S.
    Samiulla, D.
    Tiwari, N. K.
    Devaraja, T.
    Aravind, A.
    Dhudashiya, A. A.
    Booher, R.
    Daginakatte, G.
    Antony, T.
    Chelur, S.
    Nellore, K.
    Giri, S.
    Ramachandra, M.
    Samajdar, S.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S47 - S47
  • [8] SY5609, a Potent and Selective CDK7 Inhibitor, Potentiates BTK Inhibitor Activity in Mantle Cell Lymphoma Preclinical Models
    Johannessen, Liv
    Henry, Susan
    Sawant, Priyanka
    D'Ippolito, Anthony
    Ke, Nan
    Lefkowitz, Ariel
    Eaton, Matthew
    Dworakowski, Wojciech
    Rosario, Maria
    Hodgson, Graeme
    BLOOD, 2021, 138
  • [9] Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer.
    Johannessen, Liv
    Ke, Nan
    Sawant, Priyanka
    Dworakowski, Wojciech
    D'Ippolito, Anthony
    Hu, Shanhu
    Rajagopal, Nisha
    Eaton, Matthew
    Hodgson, Graeme
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo
    Hu, Shanhu
    Marineau, Jason
    Hamman, Kristin
    Bradley, Michael
    Savinainen, Anneli
    Alnemy, Sydney
    Rajagopal, Nisha
    Orlando, David
    Chuaqui, Claudio
    Olson, Eric
    CANCER RESEARCH, 2019, 79 (13)
12345